Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply

Affiliations

¹ Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita.
² Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka.
³ Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.

Comment

Yoshikazu Nakaoka et al. Rheumatology (Oxford). 2020.

. 2020 Sep 1;59(9):e48-e49.

doi: 10.1093/rheumatology/keaa255.

¹ Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita.
² Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka.
³ Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.

No abstract available

Comment on

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N. Nakaoka Y, et al. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434. doi: 10.1093/rheumatology/kez630. Rheumatology (Oxford). 2020. PMID: 31951279 Free PMC article. Clinical Trial.
Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Watanabe R. Watanabe R. Rheumatology (Oxford). 2020 Sep 1;59(9):e46-e47. doi: 10.1093/rheumatology/keaa253. Rheumatology (Oxford). 2020. PMID: 32594123 No abstract available.

1. Watanabe R. Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology 2020;59:e46–7. - PubMed
1. Nakaoka Y, Isobe M, Tanaka Y. et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology 2020;59:2427–34. - PMC - PubMed
1. Ohigashi H, Haraguchi G, Konishi M. et al. Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 2012;76:1004–11. - PubMed
1. Hellmich B, Agueda A, Monti S. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19–30. - PubMed
1. Arita Y, Nakaoka Y, Otsuki M. et al. Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis. Int J Cardiol 2015;187:319–21. - PubMed